A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite Stable Colorectal Cancer

Trial Profile

A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite Stable Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Epacadostat (Primary) ; Azacitidine; Pembrolizumab
  • Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO 206
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 03 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top